114 results on '"Gonzalez-Calle, Veronica"'
Search Results
2. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study
3. Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study
4. Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma
5. A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis
6. EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
7. MYC dysregulation in the progression of multiple myeloma
8. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients
9. Outcomes of Modified Mayo Stage IIIa and IIIb Cardiac Light-Chain Amyloidosis: Real-World Experience in Clinical Characteristics and Treatment—67 Patients Multicenter Analysis.
10. P-090 Clinical characteristics and risk of progression in patients with monoclonal gammopathy of uncertain significance: long-term experience in a single tertiary hospital
11. P-304 Triple class refractory multiple myeloma: eficacy of the new immunotherapies and new unmet medical need
12. OA-20 Genomic profiling of high-risk smoldering myeloma patients treated with a curative strategy: a biological study of the phase II GEM CESAR clinical trial
13. P-367 High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience
14. MM-202 Impact of t(11;14) in Multiple Myeloma on Response to Treatment and Survival
15. MM-198 Anti-BCMA Therapy in Multiple Myeloma: A Single-Center Experience
16. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study
17. P878: SELINEXOR IN COMBINATION WITH DARATUMUMAB-BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF RELAPSE OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS OF THE PHASE 2, MULTICENTER GEM-SELIBORDARA STUDY
18. Smoldering Multiple Myeloma: Who and When to Treat
19. Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach
20. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
21. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma
22. CAR-T Related Cytopenia Profile in Relapsed/Refractory Multiple Myeloma: Results of Patients Treated with ARI0002h, an Academic BCMA-Directed CAR-T Cell
23. Clonal Architecture and Evolution of Waldenström's Macroglobulinemia at the Single Cell Level
24. Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort
25. Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)
26. Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial
27. Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)
28. Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma
29. Results from a Pilot Study of ARI0002h, an Academic BCMA-Directed CAR-T Cell Therapy with Fractionated Initial Infusion and Booster Dose in Patients with Relapsed and/or Refractory Multiple Myeloma
30. Correlative Biological Studies Related to the Response, Peak and Persistence of ARI0002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
31. Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd
32. ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety after Fractionated Initial Therapy and Booster Dose in 60 Patients with Relapsed/Refractory Multiple Myeloma
33. Minimally Invasive Assessment of Measurable Residual Disease (MRD) in Multiple Myeloma (MM)
34. Clinical Significance of Measurable Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Chimeric Antigen Receptor (CAR) T Cells and T-Cell Engagers (TCE)
35. Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial
36. MM-341 Clinical Characteristics and Risk of Progression in Patients With Monoclonal Gammopathy of Uncertain Significance (MGUS): Long-Term Experience in a Single Tertiary Hospital
37. POSTER: MM-341 Clinical Characteristics and Risk of Progression in Patients With Monoclonal Gammopathy of Uncertain Significance (MGUS): Long-Term Experience in a Single Tertiary Hospital
38. Is there a role for new drugs with alkylating properties in multiple myeloma?
39. Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd
40. Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial
41. Recovery of policlonal immunoglobulins as a predictor factor of increased progression-free survival and overall survival in patients with multiple myeloma ineligible for ASCT
42. Prognostic implications of MRD assessment in multiple myeloma patients: comparison of Next-Generation Sequencing and Next-Generation Flow
43. Lenalidomide maintenance based on a genetic profile
44. Evaluation of Revised International Staging System for Transplant-Eligible Multiple Myeloma Patients
45. Lenalidomide Inhibits Thioredoxin Reductase (TrxR) in Multiple Myeloma (MM) Cells but Direct Inhibition of Trxr and Thioredoxin (Trx) Can Bypass Requirement of Cereblon (CRBN)
46. MYCdysregulation in the progression of multiple myeloma
47. Prognostic Factors in Systemic Light-Chain Amyloidosis with Cardiac Involvement. Single Center Experience at the University Hospital of Salamanca
48. Improving the conditioning regimen in multiple myeloma
49. Poster: MM-202 Impact of t(11;14) in Multiple Myeloma on Response to Treatment and Survival
50. Poster: MM-198 Anti-BCMA Therapy in Multiple Myeloma: A Single-Center Experience
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.